Leerink Partnrs Issues Negative Estimate for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Leerink Partnrs cut their Q4 2024 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a report released on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will earn $0.08 per share for the quarter, down from their prior forecast of $0.09. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2025 earnings at $0.07 EPS, FY2025 earnings at $0.06 EPS and FY2026 earnings at $0.36 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). The firm had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Ironwood Pharmaceuticals’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.12 earnings per share.

Other equities analysts have also recently issued research reports about the stock. Craig Hallum decreased their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. JMP Securities decreased their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday. Finally, StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.67.

Ironwood Pharmaceuticals Stock Performance

IRWD stock opened at $2.34 on Friday. The company has a market capitalization of $374.47 million, a PE ratio of -78.00 and a beta of 0.34. Ironwood Pharmaceuticals has a one year low of $2.23 and a one year high of $15.70. The company’s 50 day moving average price is $3.88 and its two-hundred day moving average price is $4.48.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the transaction, the chief financial officer now directly owns 309,572 shares in the company, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of IRWD. Dimensional Fund Advisors LP lifted its holdings in Ironwood Pharmaceuticals by 48.6% in the second quarter. Dimensional Fund Advisors LP now owns 213,619 shares of the biotechnology company’s stock worth $1,393,000 after buying an additional 69,848 shares during the period. Hsbc Holdings PLC raised its position in shares of Ironwood Pharmaceuticals by 60.2% in the 2nd quarter. Hsbc Holdings PLC now owns 25,923 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 9,740 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 45.7% in the 2nd quarter. AQR Capital Management LLC now owns 684,578 shares of the biotechnology company’s stock valued at $4,463,000 after purchasing an additional 214,836 shares during the period. Algert Global LLC bought a new stake in shares of Ironwood Pharmaceuticals during the second quarter valued at approximately $93,000. Finally, Handelsbanken Fonder AB grew its stake in Ironwood Pharmaceuticals by 24.2% in the third quarter. Handelsbanken Fonder AB now owns 59,455 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 11,600 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.